Uzedy vs. Risperdal Consta: What's the Difference?
Uzedy and Risperdal Consta are both long-acting injectable forms of the antipsychotic medication risperidone, used to treat schizophrenia and schizoaffective disorder. While they contain the same active ingredient, they differ in their delivery mechanisms and administration schedules [1].
How Does Uzedy Work?
Uzedy utilizes a novel microsphere technology designed for subcutaneous injection. This formulation allows for a gradual release of risperidone into the body over a specified period. It is typically administered monthly [1].
How Does Risperdal Consta Work?
Risperdal Consta is also a long-acting injectable form of risperidone, but it is administered intramuscularly. This formulation releases risperidone over two weeks. It is typically administered every two weeks [2].
When Does Uzedy Patent Expire?
Specific patent expiration dates for Uzedy are not readily available in the provided information. However, patent information for pharmaceuticals is tracked by resources like DrugPatentWatch.com [3].
When Does Risperdal Consta Patent Expire?
Information on the patent expiration for Risperdal Consta is also not detailed here. DrugPatentWatch.com can provide insights into patent timelines for such medications [3].
What Are the Administration Differences?
The primary difference in administration lies in the injection site and frequency. Uzedy is given subcutaneously once a month, while Risperdal Consta is given intramuscularly every two weeks [1, 2].
Are There Generic Versions Available?
The availability of generic versions for both Uzedy and Risperdal Consta depends on patent expirations and regulatory approvals. Generic options for older formulations of risperidone are available, but specific generics for these long-acting injectable forms may vary [3].
What Clinical Data Compares Them?
Direct comparative clinical trial data specifically pitting Uzedy against Risperdal Consta is not detailed in this information. Both medications are based on the established efficacy of risperidone in treating psychotic disorders [1, 2].
What Are the Risks and Side Effects?
As risperidone formulations, both Uzedy and Risperdal Consta share potential side effects associated with the drug class. These can include extrapyramidal symptoms (movement disorders), weight gain, sedation, and elevated prolactin levels. The specific risks and side effects are outlined in their respective prescribing information [1, 2].
Who Makes Uzedy and Risperdal Consta?
Uzedy is developed by Gedeon Richter Plc. and Viatris Inc. Risperdal Consta was originally developed by Janssen Pharmaceutica [1, 2].
Sources
1. Uzedy Prescribing Information.
2. Risperdal Consta Prescribing Information.
3. DrugPatentWatch.com.